A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

NCT06083623 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

2282

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: TNM001
BIOLOGICAL: placebo

Sponsor

Zhuhai Trinomab Pharmaceutical Co., Ltd.